Channel Medical Partners

Stuart K. Ennis and Christopher J. Addonizio, who co-founded the firm in 2002, serve as Managing Directors and make all investment decisions jointly. Both came from investment banking backgrounds — Ennis from Lehman Brothers and Addonizio from Wasserstein Perella — before focusing their careers on medical device investing. The firm operates without a large investment committee, giving the two partners full discretion over portfolio construction and exit timing.

No. Channel explicitly focuses on companies with regulatory-cleared products and existing commercial revenue. The firm does not invest in pre-clinical, IDE-stage, or pre-revenue medical device startups. This later-stage approach means the binary regulatory risk has already been resolved before Channel commits capital.

Channel invests broadly across medical device subsectors including cardiovascular, orthopedics, surgical instrumentation, diagnostics, and neuromodulation. The firm has backed companies like CardioMEMS (heart failure monitoring, acquired by St. Jude Medical), Rhythmia Medical (electrophysiology mapping, acquired by Boston Scientific), and Intersect ENT (sinus implants, acquired by Medtronic). The firm avoids biotech, pharmaceuticals, and digital health platforms, maintaining a pure hardware and instrumentation focus.

Channel invests primarily in the United States and Western Europe, where the regulatory pathways (FDA and CE mark) are well-defined and the strategic acquirers are concentrated. The firm sources opportunities across both regions and has historically maintained a US-heavy portfolio. Channel does not invest in emerging-market medical device companies where regulatory enforcement and exit markets are less predictable.